NNKJW

XSB

A Comprehensive Appraisal Of Her2 Heterogeneity In

Di: Jacob

Methods: We evaluated 1009 CRCs for HER2 expression and HER2 amplification by immunohistochemistry and FISH, respectively, and correlated the results to .The comprehensive somatic mutation profile of HR+ and HR- HER2-positive breast tumors was elucidated to understand their molecular heterogeneity and the distinct mutation profile and related pathways are potentially relevant in the development of optimal treatment strategies for this subset of patients.Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Machida E, et al.Our work provides a comprehensive multiomics HER2-low breast cancer dataset and suggests that the distinct nature, interpatient heterogeneity, and racial and ethnic differences of HER2-low breast cancer are dependent on HR status, and these features were more marked in the HR-negative subgroup. The molecular heterogeneity and distinct features of HER2-low breast cancers, particularly in the Chinese population, are not well . HER2-positive breast cancer is a biologically and .Neoadjuvant therapy is an important component of the comprehensive management of early breast cancer. Article 05 August 2023. A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer. HER2 heterogeneity and HER2 low status are gaining therapeutic relevance.Human epidermal growth factor receptor 2 (HER2) is a protooncogene that encodes epidermal growth factor receptor with tyrosine kinase activity, located on chromosome 17 at q21. 4 This observation, followed by inspired and .In the post hoc analysis of the HER2 screening data in the ToGA trial, a comprehensive (IHC scores 1+, 2+, 3+) HER2 staining heterogeneity of about 50% was detailed and was shown to be at its greatest in the lower IHC categories (IHC score 1+ and score 2+).The gene that encodes HER2 ( ERBB2, formerly known as neu) is amplified and overexpressed in approximately 20% of newly diagnosed breast cancers.Emerging data suggests that HER2 intratumoral heterogeneity (ITH) is associated with therapy resistance, highlighting the need for new strategies to assess HER2 ITH.Molecular heterogeneity in metastatic breast cancer presents multiple clinical challenges in accurately characterizing and treating the disease.HER2-positive (HER2+) breast cancer is clinically and biologically a heterogenous disease and not all patients benefit to the same extent from current anti-HER2 therapies. Taiki Hashimoto, Daisuke Takayanagi, .govBreast Cancer, HER2 Mutations, and Overcoming Drug .As a result, average Ki67%, obtained by the DIA for each tumor, is supplemented by comprehensive quantitative characteristics of the intratumor variance (heterogeneity) of Ki67 expression (e.HER2 is a key oncogenic driver and a therapeutic target in other solid tumors, including CRC, where HER2 overexpression or amplification ranges from 1. Hashimoto, T; Takayanagi, D; Yonemaru, J; Naka, T; Nagashima, K .Europe PMC is an archive of life sciences journal literature.comHER2: An emerging target in colorectal cancer – PubMedpubmed.

Targeting HER2 heterogeneity in breast and gastrointestinal cancers

Quantification of HER2 and estrogen receptor heterogeneity in breast ...

Targeting HER2 heterogeneity in early-stage breast cancer

Interaction of host immunity with HER2-targeted treatment and tumor ...

Two sections from a gastric adenocarcinoma, with HER2 heterogeneity. On ...

A comprehensive appraisal of HER2 heterogeneity in HER2

We also characterised HER2 expression statuses in CRCs.orgHER2 targeted therapy in colorectal cancer: New horizonspubmed.The role of HER2 and HER3 in HER2-amplified cancers . The role of HER2 . PCR-based assays allow quantitative determination of . The introduction of trastuzumab for anti-HER2 therapy dramatically changed the clinical outcome for HER2 (ERBB2, neu) positive breast cancer patients. HER-3 surface expression increases in advanced colorectal cancer .We show that HER2 heterogeneity, particularly the fraction of ERBB2 nonamplified cancer cells, is a strong predictor of resistance to HER2 therapies and could potentially be used .The study highlights the temporal and spatial heterogeneity of HER2 status between primary CRC and corresponding liver metastases and raises the question of a sequential .The heterogeneity of articles was assessed using I 2 statistics, and scores of 75%, 50%, and 20% correspond to high, moderate, and low levels of heterogeneity, respectively .This system addresses the tissue heterogeneity of HER2 expression, providing a comprehensive view and achieving a high HER2 score classification accuracy of .In the era of precision medicine, it may be of importance to acknowledge the existence of HER2 heterogeneity in tumors and to take this information into account when biopsies of HER2-positive breast cancers are subjected to genomic analyses, as the repertoire of somatic genetic alterations may differ between the HER2-positive and HER2-negative . However, there is an increasing awareness of how frequently tumors have low or heterogeneous . 2023; 129:1176–1183.Targeting HER2 heterogeneity in breast cancer – PubMedpubmed.Breast cancer is a heterogeneous disease, at both an inter- and intra-tumoural level. We also revealed a potential driving . Search life-sciences literature (42,833,164 articles, preprints and more)HER2 amplification heterogeneity is associated with resistance to trastuzumab emtansine in the neoadjuvant setting, emphasizing the importance of assessing whether .govEmpfohlen auf der Grundlage der beliebten • Feedback

A comprehensive appraisal of HER2 heterogeneity in HER2

orgEmpfohlen auf der Grundlage der beliebten • Feedback

A comprehensive appraisal of HER2 heterogeneity in HER2

We aimed to qualitatively and quantitatively analyze, through a systematic review and meta-analysis, the current evidence on the differential expression of the hallmarks of cancer in . A socio-ecological model was used to .comEmpfohlen auf der Grundlage der beliebten • Feedback0 in more than 50% of cells by FISH [30] ( Table 1 ).Receptor, ErbB-2.In this review article we will document the changes that have contributed to a better evaluation of the HER2 status in clinical practice, furthermore we will discuss HER2 . HER2 heterogeneity can be a determi-nant of response and resistance .1038/s41416-023-02382-z. 2023 Oct 19;129(7):1176-1183. However, acquired and inherent .The molecular heterogeneity and distinct features of HER2-low breast cancers, particularly in the Chinese population, are not well understood, limiting its precise management in the era of antibody‒drug conjugates. Tumor infiltrating lymphocytes are frequent, predictive and prognostic in HER2+ BC.

Targeting HER2 heterogeneity in breast cancer

It not only makes surgery possible for inoperable patients but also .We also performed a subgroup analysis (such as with sample sizes) and a meta-regression to explore the potential sources of heterogeneity.A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer HER2扩增和低HER2结直肠癌HER2异质性的综合评价 网址

Survival analyses of HER2 heterogeneity and Lauren classification. (A ...

HER2 positivity was defined by IHC and FISH using colorectal cancer-specific HERACLES diagnostic criteria which are defined as tumours with HER2 3+ score in more than 50% of cells by IHC or with HER2 2+ and a HER2: CEP17 ratio higher than 2.METHODS: We evaluated 1009 CRCs for HER2 expression and HER2 amplification by immunohistochemistry and FISH, respectively, and correlated the results to .In breast cancers, HER2 gene is amplified in 15%–20% of invasive breast cancers and its amplification is closely linked to HER2 protein overexpression [1,2].

Targeting HER2 heterogeneity in breast and gastrointestinal cancers ...

In summary, we propose a methodology, based on HexT of IHC DIA data, to retrieve comprehensive information about biomarker expression, its intra-tissue variance, and spatial heterogeneity indicators and to provide effective ways to visualize intra-tissue heterogeneity for decision support and quality assurance.comHER2 in metastatic colorectal cancer: a new to target to .A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer Article 05 August 2023.HER2 expression and overexpression is characterized by spatial and temporal heterogeneity. We also characterised HER2 .This study aimed to elucidate the clinicopathological and molecular features of HER2 -amplified and HER2-low colorectal cancers (CRCs).The human epidermal growth factor receptor 2 (HER2) is a well-known negative prognostic factor in breast cancer and a target of the monoclonal antibody trastuzumab . [PMC free article] [Google Scholar]govEvolving concepts in HER2 evaluation in breast cancer: .HER2-positive BC is biologically a heterogeneous group depending on HER2 activation mechanisms, hormone receptor status, genome variations, tumor heterogeneity, and treatment resistance, which affect the treatment benefit and patients‘ outcomes. We also characterised HER2 expression statuses in CRCs focusing on their intratumoral heterogeneity and alterations in metastatic lesions to establish practical HER2 status assessment.HER2 heterogeneity was associated with no pCR, basal-like features, and low ERBB2 expression yet high ERBB signaling sustained by activation of downstream pathway . People living with the human Immune deficiency virus (PLHIV) are more susceptible to tuberculosis (TB), which is a leading cause of mortality (1, 2).A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer Article 05 August 2023 HER2-targeted therapies — a role beyond breast cancer

EGFR, HER2, and HER3 protein expression in paired primary

Gastro-oesophageal carcinoma (GOC) represents the third . Today, patients eligible for trastuzumab are selected using HER2 expression/amplification status of the primary tumor.Immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) are currently the most commonly used methods to assess HER2 status.Background This study aimed to elucidate the clinicopathological and molecular features of HER2-amplified and HER2-low colorectal cancers (CRCs).According to the latest American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) Guidelines for HER2 testing, HER2-negative breast cancers . This review will discuss HER2 alternations (gene amplification or receptor overexpression) in BC, .As a representative of potential “hidden champions”, a concept originating in Germany, specialized and innovative Little Giant Enterprises (LGEs) have become exemplary . HER2 heterogeneity can be a determinant of response and resistance to .Article A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer Detailed information of the J-GLOBAL is an information service . Appreciating heterogeneity through the application of biomarkers and molecular . EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph ., spatial entropy, bimodality, etc. The identification of Human epidermal growth factor receptor 2 (HER2) as a target in breast cancer and the subsequent development of HER2-targeted therapies has revolutionized the treatment of patients with HER2-positive breast cancer. In HERACLES-A, 914 patients with KRAS exon 2 wild .4% in different studies; this variability may be due to small study populations, heterogeneity in clinicopathological characteristics (stage, location), different antibodies used for . Shigeki Sekine. Most relevant mutations are found in ERBB2 (∼4 %) and PI3K/AKT/mTOR pathway (>30 %). NTRK fusion in Japanese colorectal adenocarcinomas Article Open access 11 . This study aimed to elucidate the clinicopathological and molecular features of HER2 -amplified and HER2-low colorectal cancers (CRCs).Almost 50 % of HER2+ breast cancer (BC) are molecularly HER2-Enriched (HER2-E). In addition, hexagons representing the upper quintile of the local Ki67% distribution indicate approximately 20 % of the . Current diagnostic approaches offer limited ability .2023年10月，《Nature》子刊《British Journal of Cancer》发表了一篇题为《A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low .The molecular heterogeneity and distinct features of HER2-low breast cancers, particularly in the Chinese population, are not well understood, limiting its precise management in the era of . If assessment of heterogeneity was limited only to IHC 3+ cases, as in many other .The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to .A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer. To address this issue, we established a cohort of 434 Chinese patients with HER2-low breast cancer (433 female and one male) and . In this study, we .

HER2 targeted therapy in colorectal cancer: New horizons

British Journal of Cancer .govHistopathologic features and molecular genetic landscape ofnature.Heterogeneous HER2 Amplification—a New Clinical Category .